Results 231 to 240 of about 701,268 (244)

Mitotic Index and Progression-Free Survival in Atypical Meningiomas

World Neurosurgery, 2020
Extent of resection and tumor grade are considered the most important predictors of progression-free survival (PFS) in meningiomas. However, adjuvant therapy for atypical meningiomas remains controversial, with variable PFS rates of up to 40%. The current mitotic index (MI) range for atypical meningiomas is broad, comprising all tumors with >4 and
Ricardo A. Domingo, Shashwat Tripathi, Tito Vivas-Buitrago, Victor M. Lu, Kaisorn L. Chaichana, Alfredo Quiñones-Hinojosa   +5 more
openaire   +2 more sources

Classification of progression free survival with nasopharyngeal carcinoma tumors

SPIE Proceedings, 2016
Nasopharyngeal carcinoma (NPC) is an abnormal growth of tissue which arises from the back of the nose. At the time of diagnosis, detection of tumor features with prognostic significance, including patient demographics, imaging characteristics and molecular characteristics, can enable the treating clinician to select a treatment that is optimized for ...
Hamidreza Farhidzadeh, Joo Y. Kim, Jacob G. Scott, Dmitry B. Goldgof, Lawrence O. Hall, Louis B. Harrison   +5 more
openaire   +1 more source

Evaluating and Adjusting for Premature Censoring of Progression-Free Survival

Journal of Biopharmaceutical Statistics, 2013
The intent-to-treat principle, grouping subjects as they were randomized and following all subjects to the endpoint or the end of study, allows valid statistical comparisons. Progression-free survival (PFS) has been used as a decision-making endpoint in oncology.
Mark, Rothmann, Kallappa, Koti, Kyung Yul, Lee, Hong Laura, Lu, Yuan Li, Shen, Jenny J, Zhang, Mei, Jin, Haojin, Zhou   +7 more
openaire   +2 more sources

Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design

Therapeutic Innovation & Regulatory Science
Overall survival (OS) remains the gold-standard endpoint in oncology trials, while progression-free survival (PFS) is a widely used surrogate endpoint that captures tumor progression earlier. However, an increase in PFS has not necessarily led to an improvement in OS (Reck M, 2009). The recent CodeBreaK 200 trial, a randomized, open-label Phase 3 study
Zhoujingpeng, Wei, Yuanyuan, Han, Luoying, Yang, Pourab, Roy, Chunsheng, He, Liangang, Liu, Shu-Pang, Huang, Hsin-Ju, Hsieh   +7 more
openaire   +2 more sources

Progression-free survival as a surrogate for overall survival in advanced cancer.

Journal of Clinical Oncology, 2015
e17765 Background: Progression-free survival (PFS) is sometimes being used instead of overall survival (OS) as a primary end-point in clinical trials of advanced cancer patients (ACP).
Eric Gillies, Veera Holdai, David Eric Cowall   +2 more
openaire   +1 more source

Progression-free survival: it is time for a new name

The Lancet Oncology, 2022
Bishal, Gyawali, Elizabeth, Eisenhauer, Michelle, Tregear, Christopher M, Booth   +3 more
openaire   +2 more sources

Progression Free Survival

2010
openaire   +1 more source

Progression-Free Survival

2011
openaire   +1 more source

NEJ026 trial: progression-free survival benefit is not enough

The Lancet Oncology, 2019
openaire   +2 more sources

Valid Analysis of Brain-Specific Progression-Free Survival

JAMA Oncology
Stephanie, Armbruster, Ethan B, Ludmir, Lee-Jen, Wei   +2 more
openaire   +4 more sources